Rare vertebral metastasis in a case of Hereditary Paraganglioma
© Ribeiro da Silva et al.; licensee BioMed Central Ltd. 2012
Received: 8 May 2012
Accepted: 6 September 2012
Published: 21 September 2012
Paragangliomas are rare tumours with a prevalence of 1/10000 to 1/30000. Tumors arising from the paraganglia are characteristically of low malignant potential. Vertebral metastases are exceedingly rare, and only isolated case reports have described them. The authors present the clinical course of a 47 years-old female patient with a familial paraganglioma [PGL] with vertebral metastastization, who underwent an intralesional tumor excision and corpectomy. Genetic screening demonstrated a new germinal frameshift mutation of the SDHB exon 6 [c.587-591DelC]. After surgery there was normalization of the analytical parameters and imagiologic screening. One year later she presented a new image in the the pedicle of T11 on the contralateral side of the surgical incision. She performed 2 treatments with MIBG and 1 cicle of radiotherapy that made the new lesion regress. Currently the patient does not present any clinical or analytical evidence of new metastasis.
This case outlines the clinical course of a patient with a PGL syndrome for whom a rare vertebral metastasis was diagnosed. It highlights the importance of identifying patients with germline SDHB mutations, as these patients are at a high risk of developing malignant disease.
KeywordsFamiliar Paraganglioma Vertebral Metastization SDHB
The paragangliomas/pheochromocytomas are rare tumours with a prevalence of 1/10000 to 1/30000 . The sympathetic-associated paragangliomas [PGL] arise from the adrenal medulla or from the sympathetic ganglia that extend along the paravertebral axis from the neck to the abdomen and pelvis. These tumors are usually functionally active and secrete either catecholamines or metanephrines. The parasympathetic-associated paragangliomas arise in the head and neck region and middle mediastinum, and are usually nonfunctioning. The term pheochromocytoma is commonly used for a tumor located in the adrenal gland .
Hereditary cases represent 35% of all pheochromocytoma and paraganglioma and are associated with gene mutations. All cases display an autosomal dominant inheritance pattern with incomplete penetrance and variable expression [3, 4].
Tumors arising from the paraganglia are characteristically of low malignant potential, with only 10% developing distant spread. The great majority of metastasizing tumors has evidence of distant spread at diagnosis. Fifty percent are located at the cervical lymph nodes, and the others are evenly distributed among bone, lung and liver. Vertebral metastases are exceedingly rare, and only isolated case reports have described them .
The authors present the clinical course of a 47 years-old female patient with a familial paraganglioma, for whom an unusual vertebral metastasis was identified and treated.
37 years-old caucasian female, without known diseases until 1997, when she complains of headaches, restless feeling, anxiety and palpitations, symptoms that she attributes to stress. Routine screening showed hypertension that was resistant to medical treatment. Laboratory analyses demonstrated an elevation in the 24 h dosage of vanilmandelic acid [VMA]: 52 mg/24 h [N: 1.4 – 6.5]; epinephrine: 21 μg/24 h [N 0–20]; norepinephrine: 3161 μg/24 h [N: 23–105]; dopamine: 711 μg/24 h [N: 65–400]; metanephrine: 91 μg/24 h [N: 52–341]; normetanephrine: 3546 μg/24 h [N 88–444]. Abdominal CT showed a 5.2 cm mass in the region of the left adrenal gland, with a corresponding hyperfixation in the MIBG scintigraphy. She underwent surgery for exploration and removal of the lesion. Intraoperatively it was found that the lesion was separated from the adrenal gland. This finding together with the pathologic report of a neoplasia invading the capsule, not going beyond it, and images of venous invasion made the diagnosis of malignant paraganglioma. Genetic screening of the patient demonstrated a new germinal frameshift mutation of the SDHB exon 6 [c.587-591DelC]. There was a family history of a cousin diagnosed at 13 years of age with a dopamine producing malignant paraganglioma, that died at 30 years of age with wide spread metastasis [cranial and lumbar].
The prevalence of catecholamines or metanephrines secreting tumors in cases of hereditary pheochromocytoma and paraganglioma disorders is 10–20% in patients with von Hippel–Lindau disease, approximately 40% in patients with multiple endocrine neoplasia type 2A and 2B, and 0.1–5.0% in patients with neurofibromatosis type 1[6, 7].
The incidence of pheochromocytoma is 0.001 in the general population. There aren’t reports stating the real incidence of paragangliomas, but it is consensual that it is far bellow the incidence of pheocromocytoma. The malignant diagnosis is noted according to whether metastasis or invasion exists.
Paragangliomas are commonly bilateral and may be multicentric. Multicentricity occurs in approximately 10% of tumors. Paragangliomas characteristically have a slow and unpredictable growth pattern, making it difficult to determine the natural history of the disease .
There are five types of familial paraganglioma [PGL] syndromes that have been identified with mutations in the SDH genes that encode subunits of the heterotetrameric SDH complex. SDH is involved in oxidation of succinate to fumarate in the Krebs cycle and provides electrons to the mitochondrial electron transport chain .
Investigation has revealed that SDHD mutations [PGL type 1] are associated with multifocal head and neck paragangliomas, whereas SDHB mutations [PGL type 4] are associated with extra-adrenal disease and malignancy [8, 9].
Several studies have suggested that patients who are carriers of the SDHB mutation [PGL type 4], like the patient we describe, are more likely to develop extra-adrenal lesions [abdominal or thoracic] and malignant disease .
The WHO defines malignant pheochromocytomas and paragangliomas as metastatic disease at sites where chromaffin tissues are not usually present. Metastatic sites include the lungs, bones, liver, and lymph nodes. Malignant tumors are typically larger, have a higher mitotic count, have extensive local or vascular invasion and express fewer peptides on immunohistochemical studies compared with benign tumors .
There is little correlation between histologic appearance and malignant potencial. Tumors with significant atypia and pleomorphism have often behaved in benign fashion, possibly because they were removed before metastasis. Benign-appearing tumors can behave in aggressive fashion. Several authors have found that the presence of mitosis in the pathologic specimen correlated significantly with malignancy . In these series, mitotic figures were seen in all malignant tumours.
Paragangliomas often exhibit a prolonged time interval to the development of recurrence or metastasis. Recurrence and/or distant metastases have been reported to occur from 0 to 20 years after diagnosis [3, 12].
In the current case the patient presented one local recidiva and a distant metastasis 9 and 10 years after the initial diagnosis, respectively. In both situations it was decided that the patient was eligible for surgical treatment with curative intention because these were always isolated lesions at the time of diagnosis .
The patient underwent a biannual monitoring program with physical examination and measurement of blood pressure and levels of urinary catecholamines and metanephrines . The fact that the patient presented only a solitary metastasis was the reason the authors chose to pursuit a surgical exertion, in an attempt to perform a curative treatment. It was taken under consideration the fact that metastatic paraganglioma, like pheochromocytoma, is relatively radioresistant, as compared with lymphoma and breast cancer .
The reason to choose a surgical intervention instead of chemotherapy in the T11 lesion was also based in the risk of vertebral colapse with the consequent danger of neurological injury . The exertion of the lesion and the replacement by a titanium cage and ilac gaft was considered to be a better mechanical solution for the patient, besides the fact that we intended to have a curative procedure. Nevertheless a new recidiva was diagnosed one year later. An en bloc excision would probably have been more appropriate, but at the time we were not performing this routinely.
Nevertheless, this proved to be at least partially a correct decision because the patient became assymptomatic and was able to resume working [she is still working and with no clinical complaints].
One could argue that she should have had chemotherapy with MIBG imediately after the removal of the vertebral metastasis because it was the second recidiva, but it was decided against that in group reunion. It was taken in consideration that chemotherapy does not seem to increase the survival in women with metastatic malignant paraganglioma .
When the local vertebral recidiva occurred it was decided that the patient would undergo MIBG treatment. This option led to a regression in tumour size. Even in this perpective the surgical procedure was benefic to the patient because the dose of MIBG used is size dependent.
The patient's direct family was offered genetic screening, having been diagnosed 5 positive patients, and one already died of metastatic pheocromocytoma .
This case outlines the clinical course of a patient with a PGL type 4 syndrome for whom a rare vertebral metastasis was diagnosed. The case highlights the importance of offering targeted genetic testing for the SDHB gene mutations to a patient with multiple, extra-adrenal paragangliomas and a family history of malignant paraganglioma. It also illustrates the importance of identifying patients with germline SDHB mutations, as these patients are at a high risk of developing malignant disease. On the other hand it also highlights the importance of a multidisciplinary approach to these patients, as well as an aggressive attitude towards metastasis, with radical surgical exertion of the tumor being, whenever it is possible, the authors’ choice.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Neumann HPH, et al.: Pheocromocytoma. In Harrison’s Principles of internal medicine. Vol 2. 17th edition. Edited by: Fauci . McGraw Hill Medical; 337: 2269–2275
- Kimura N, Chetty R, Capella C, Young WF, Koch CA, Lam KY, DeLellis RA, Kawashima A, Komminoth P, Tischler AS: Extra-adrenal paraganglioma: carotid body, jugulotympanic, vagal, laryngeal, aortico-pulmonary. In World Health Organization classification of tumours pathology and genetics: tumours of endocrine organs. Edited by: DeLelis RA, Lloyd RV, Heitz PU, Eng C. IARC Press, Lyon France; 2004:159–161.Google Scholar
- Neumann HP, Pawlu C, Bausch B, Peczkowska M, McWhinney SR, Muresane M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C: Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004, 294: 943–951.View ArticleGoogle Scholar
- Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Valimaki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G, Neumann HPH: Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHB and SDHD. JAMA 2005, 294: 2057–2063. 10.1001/jama.294.16.2057View ArticlePubMedGoogle Scholar
- Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PLM, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG: Clinical presentations and penetrance of pheochromocytoma and paraganglioma syndromes. J Clin Endocrinol Metab 2006, 91: 827–836.View ArticlePubMedGoogle Scholar
- Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treir M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng : Germ line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002, 346: 1459–1466. 10.1056/NEJMoa020152View ArticlePubMedGoogle Scholar
- Baush B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M, Cascon A, Harenberg T, Schiavi F, Pawlu C, Peczkowska M, Letizia C, Calvieri S, Arnaldi G, Klingenberg-Noftz RD, Reisch N, Fassina A, Brunaud L, Walter MA, Mannelli M, MacGregor G, Palazzo FF, Barontini M, Walz MK, Kremens B, Brabant G, Pfaffle R, Koschker AC, Lohoefner F, Mohaupt M, Gimm O, Jarzab B, McWhinney SR, Opocher G, Januszewicz A, Kohlhase J, Eng C, Neumann HP: Germline NF1 mutational spectra and loss of heterozigosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007, 92: 2784–2792. 10.1210/jc.2006-2833View ArticleGoogle Scholar
- Baysal BE, Ferrel RE, Willet-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, Van der Mey A, Taschner PEM, Rubinstein Meyers EN, Richard CW, Cornelisse CJ, Devilee P, Devlin B: Mutations in SDHD, a mitocondrial complex II gene, in hereditary paraganglioma. Science 2000, 287: 848–851. 10.1126/science.287.5454.848View ArticlePubMedGoogle Scholar
- Niemann S, Muller U: Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000, 26: 268–270. 10.1038/81551View ArticlePubMedGoogle Scholar
- Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER: Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and familial paraganglioma. Am J Hum Gent 2001, 69: 49–54. 10.1086/321282View ArticleGoogle Scholar
- Lloyd RV, Kovacs K, Young WF, Farrell WF, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheitauher BW, Horvath E: Pituitary tumors: Introduction. In World Health Organization classification of tumours pathology and genetics: tumours of endocrine organs. Edited by: DeLelis RA, Lloyd RV, Heitz PU, Eng C. IARC Press, Lyon France; 2004:10–13.Google Scholar
- Young WF: Paragangliomas: clinical overview. Annals of the New York Academy of Science 2006, 1073: 21–29. 10.1196/annals.1353.002View ArticleGoogle Scholar
- Manneli M: Management and Treatment of Pheochromocytomas and Paragangliomas. Annals of the New York Academy of Science 2006, 1073: 405–416. 10.1196/annals.1353.044View ArticleGoogle Scholar
- Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K: Biochemical diagnosis of paraganglioma: how to distinguish true from false positive test results. J Clin Endocrinol Metab 2003,88(6):2656–2666. 10.1210/jc.2002-030005View ArticlePubMedGoogle Scholar
- Olson JJ, Loftus CM, Hitchon PW: Metastatic pheochromocytoma of the cervical spine. Spine 1989,14(3):349–351. 10.1097/00007632-198903000-00018View ArticlePubMedGoogle Scholar
- Noruma K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, Takano K: Survival of patients with metastatic malignat pheochromocytoma and efficacy of combined cyclosphosphamide, vincristine, and dacarbazine chemotherapy. JCEM 2009, 94: 2850–2856.Google Scholar
- Erlic Z, Neumann HPH: Clinical questions: when should genetic testing be obtained in a patient with pheochromocytoma or paraganglioma? Clin Endocrinol 2009, 70: 354–357. 10.1111/j.1365-2265.2008.03480.xView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.